Par Pharm Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PAR PHARM, and what generic alternatives to PAR PHARM drugs are available?
PAR PHARM has one hundred and fifty-three approved drugs.
There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.
There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and eighty-nine supplementary protection certificates in fifteen countries.
Summary for Par Pharm
International Patents: | 9 |
US Patents: | 1 |
Tradenames: | 98 |
Ingredients: | 96 |
NDAs: | 153 |
Patent Litigation for Par Pharm: | See patent lawsuits for Par Pharm |
PTAB Cases with Par Pharm as petitioner: | See PTAB cases with Par Pharm as petitioner |
Drugs and US Patents for Par Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Par Pharm | PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE | amitriptyline hydrochloride; perphenazine | TABLET;ORAL | 070621-001 | Sep 11, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Par Pharm Inc | TIZANIDINE HYDROCHLORIDE | tizanidine hydrochloride | CAPSULE;ORAL | 207199-002 | Mar 14, 2017 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Par Pharm | LAMOTRIGINE | lamotrigine | TABLET, EXTENDED RELEASE;ORAL | 201791-005 | Jan 18, 2013 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Par Pharm | THIORIDAZINE HYDROCHLORIDE | thioridazine hydrochloride | TABLET;ORAL | 088322-001 | Dec 5, 1983 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Par Pharm
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Par Pharm | NASCOBAL | cyanocobalamin | GEL, METERED;NASAL | 019722-001 | Nov 5, 1996 | 4,724,231 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PAR PHARM drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Nasal Spray | 500 mcg/spray | ➤ Subscribe | 2017-04-28 |
International Patents for Par Pharm Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 101163679 | ⤷ Try a Trial |
South Korea | 20080000660 | ⤷ Try a Trial |
European Patent Office | 1948613 | ⤷ Try a Trial |
Australia | 2006240490 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Par Pharm Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3342411 | 122020000008 | Germany | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS; REGISTRATION NO/DATE: EU/1/09/538/001-008 20110824 |
2236132 | C300714 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718 |
2563920 | CR 2019 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710 |
3351246 | CA 2019 00056 | Denmark | ⤷ Try a Trial | PRODUCT NAME: EVEROLIMUS; REG. NO/DATE: EU/1/09/538/001-008 (K(2012)5347) 20120725 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.